Portal de Periódicos da CAPES

Effectiveness and Safety of a Single-Dose Ivermectin Treatment for Uncomplicated Strongyloidiasis in Immunosuppressed Patients (ImmunoStrong Study): The Study Protocol

2021; Multidisciplinary Digital Publishing Institute; Volume: 10; Issue: 7 Linguagem: Inglês

10.3390/pathogens10070812

2076-0817

Fernando Salvador, Ana Lucas Dato, Sílvia Roure, Marta Arsuaga, Asunción Pérez-Jacoiste, Magdalena García-Rodríguez, José A. Pérez‐Molina, Dora Buonfrate, José María Saugar, Israel Molina,

Parasitic Diseases Research and Treatment

Strongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a prospective observational study aiming to evaluate the effectiveness and safety of a single-dose ivermectin for treatment of uncomplicated strongyloidiasis in immunosuppressed patients. The secondary objectives are to assess accuracy of molecular techniques for the follow-up of these patients and to determine the population pharmacokinetics of ivermectin. The information retrieved by this study will cover relevant information gaps in the strongyloidiasis management among immunosuppressed patients.